Going Public: Trends in the IPO Market
June 2006
Going Public: Trends in the IPO Market
The Second Edition of PharmaVentures Business Review
Watch the whole program
Going Public: Trends in the IPO Market
In this month's edition of the PharmaVentures® Business Review, we take a look at what is happening in the world of biotech initial public offerings (IPOs) and the issues currently facing those companies intent on seeking the potential rewards that going public has to offer. We examine the trends in biotech IPO launches in both the US and UK markets and hear what the experts have to say about the promises and pitfalls of undertaking an IPO. In addition, we have the usual round-up of the most important biotech and pharmaceutical deals that have taken place during the last month.
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- Abraxis BioScience's acquisition of AstraZeneca's US-branded anaesthetic and analgesic injectables portfolio
- Astellas Pharma's licensing deal with FibroGen for novel anaemia treatments
- Solvay Pharmaceuticals US$298 M Influenza Vaccine contract with US HHS
- GSK's US$274 M Influenza Vaccine contract with US HHS
- Novartis' US$220 M Influenza Vaccine contract with US HHS
- DynPort Vaccine Company's US$242.5 M Influenza Vaccine contract with US HHS
- Merck & Co.'s US$400 M acquisition of GlycoFi
- MedImmune's US$170 M Influenza Vaccine contract with US HHS
- AstraZeneca's billion-dollar acquisition of Cambridge Antibody Technology (CAT)
Watch this segment
The Month in Review
We cover the following key deals:
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- Abraxis BioScience's acquisition of AstraZeneca's US-branded anaesthetic and analgesic injectables portfolio
- Astellas Pharma's licensing deal with FibroGen for novel anaemia treatments
- Solvay Pharmaceuticals US$298 M Influenza Vaccine contract with US HHS
- GSK's US$274 M Influenza Vaccine contract with US HHS
- Novartis' US$220 M Influenza Vaccine contract with US HHS
- DynPort Vaccine Company's US$242.5 M Influenza Vaccine contract with US HHS
- Merck & Co.'s US$400 M acquisition of GlycoFi
- MedImmune's US$170 M Influenza Vaccine contract with US HHS
- AstraZeneca's billion-dollar acquisition of Cambridge Antibody Technology (CAT)
Watch this segment
The Business Report
In this month's Business Report, we focus on some of the trends that business analysts at PharmaVentures have been observing in the biotech IPO landscape. We consider both long- and short-term trends in IPOs across the globe and take a closer look at some of the biotech companies that have gone public this year in order to gain an important insight into the status of the biotech IPO market-place as it stands, halfway through 2006.
Watch this segment
Meet the Experts
Fintan Walton, CEO PharmaVentures, leads this month's international panel in a discussion about IPOs in the biotech industry, drawing on the wide-ranging experiences of our experts to address the practical realities that face companies hoping to enter the public market, and the options available for them to do so. Topics covered include current IPO market conditions in Europe, alternative IPO launch strategies and the knock-on effects that changes in the IPO market could have on early-stage funding.
On this month's panel:
Dr Michael Kauffman,
CEO Predix Pharmaceuticals
Robert Miller,
CEO Phynova
Charles Walker,
Director, Nomura Code Securities
Extra This Month - Exclusive Interviews
Charles Hutchinson, CEO of GlycoFi, talks to PharmaVentures about his company's acquisition by Merck & Co.
(Photo by Jon Gilbert Fox)
Bram Palache, Head of Global Communications for Influenza Vaccines at Solvay Pharmaceuticals, talks to PharmaVentures about winning the company's US$298 M contract with the US HHS to develop cell-based influenza vaccines. (listen to the full interview)
